Christian J. Braun
Christian J. Braun
Max Eder Group leader at LMU Munich
Verified email at - Homepage
Cited by
Cited by
p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest
CJ Braun, X Zhang, I Savelyeva, S Wolff, UM Moll, T Schepeler, TF Ørntoft, ...
Cancer research 68 (24), 10094-10104, 2008
Gene therapy for Wiskott-Aldrich syndrome—long-term efficacy and genotoxicity
CJ Braun, K Boztug, A Paruzynski, M Witzel, A Schwarzer, M Rothe, ...
Science translational medicine 6 (227), 227ra33-227ra33, 2014
Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndromeHuman IL-21R deficiency
D Kotlarz, N Ziętara, G Uzel, T Weidemann, CJ Braun, J Diestelhorst, ...
The Journal of experimental medicine 210 (3), 433-443, 2013
Sensitizing protective tumor microenvironments to antibody-mediated therapy
CP Pallasch, I Leskov, CJ Braun, D Vorholt, A Drake, YM Soto-Feliciano, ...
Cell 156 (3), 590-602, 2014
Coordinated splicing of regulatory detained introns within oncogenic transcripts creates an exploitable vulnerability in malignant glioma
CJ Braun, M Stanciu, PL Boutz, JC Patterson, D Calligaris, F Higuchi, ...
Cancer cell 32 (4), 411-426. e11, 2017
A role for PVRL4-driven cell–cell interactions in tumorigenesis
NN Pavlova, C Pallasch, AEH Elia, CJ Braun, TF Westbrook, M Hemann, ...
Elife 2, e00358, 2013
Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation
CJ Braun, PM Bruno, MA Horlbeck, LA Gilbert, JS Weissman, MT Hemann
Proceedings of the National Academy of Sciences 113 (27), E3892-E3900, 2016
Minor changes in expression of the mismatch repair protein MSH2 exert a major impact on glioblastoma response to temozolomide
JL McFaline-Figueroa, CJ Braun, M Stanciu, ZD Nagel, P Mazzucato, ...
Cancer research 75 (15), 3127-3138, 2015
A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy
IG Cannell, KA Merrick, S Morandell, CQ Zhu, CJ Braun, RA Grant, ...
Cancer cell 28 (5), 623-637, 2015
Gene therapy for Wiskott-Aldrich syndrome—long-term reconstitution and clinical benefits, but increased risk for leukemogenesis
CJ Braun, M Witzel, A Paruzynski, K Boztug, C Kalle, M Schmidt, C Klein
Rare diseases 2 (1), e947749, 2014
Cell cycle arrest or apoptosis by p53: are microRNAs-192/215 and-34 making the decision?
SA Georges, BN Chau, CJ Braun, X Zhang, M Dobbelstein
Cell Cycle 8 (5), 677-682, 2009
In vivo functional screening for systems-level integrative cancer genomics
J Weber, CJ Braun, D Saur, R Rad
Nature Reviews Cancer 20 (10), 573-593, 2020
A Raf-competitive K-Ras binder can fail to functionally antagonize signaling
MJ Kauke, AW Tisdale, RL Kelly, CJ Braun, MT Hemann, KD Wittrup
Molecular cancer therapeutics 17 (8), 1773-1780, 2018
Efficacy of gene therapy for Wiskott-Aldrich-syndrome
CJ Braun, K Boztug, M Schmidt, MH Albert, A Schwarzer, A Paruzynski, ...
Blood, The Journal of the American Society of Hematology 118 (21), 165-165, 2011
Rewiring the solid tumor epigenome for cancer therapy
CJ Braun, MT Hemann
Expert review of anticancer therapy 16 (9), 977-987, 2016
Hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome
MGW Witzel, CJ Braun, K Boztug, A Paruzynski, MH Albert, A Schwarzer, ...
Blood 122 (21), 718, 2013
High-level clustering of vector integrations in the German WAS clinical gene therapy trial
A Paruzynski, K Boztug, C Ball, A Nowrouzi, A Arens, C Lulay, M Dorda, ...
MOLECULAR THERAPY 20, S212-S212, 2012
Unraveling tumor suppressor networks with in vivo RNAi
CJ Braun, MT Hemann
Cell stem cell 12 (6), 639-641, 2013
Functional screens identify coordinators of RNA molecule birth, life, and death as targetable cancer vulnerabilities
CJ Braun, MT Hemann
Current opinion in genetics & development 54, 105-109, 2019
Gene therapy for Wiskott–Aldrich syndrome
MGW Witzel, CJ Braun, K Boztug, C Klein
Expert Opinion on Orphan Drugs 1 (9), 705-715, 2013
The system can't perform the operation now. Try again later.
Articles 1–20